NCT05016778: Phase 1: (OriCAR-017) - CAR-T Cells Targeting GPRC5D in the Treatment of RRMM - POLARIS
Updated: Sep 29
CAR-T Cells Targeting GPRC5D in the Treatment of Relapsed / Refractory Multiple Myeloma (POLARIS)
NCT05016778: Phase 1: A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple Myeloma
A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple Myeloma
This is a single-arm, open-label, dose-escalation study to evaluate the safety, tolerability, cellular kinetics and initial efficacy of CAR-T cell therapy targeting GPRC5D in multiple myeloma subjects who have failed the standard treatments.
The first affiliated hospital of medical college of zhejiang university
Hangzhou, Zhejiang, China, 310003
ClinicalTrials.gov Identifier: NCT05016778
Official Title: A Single Arm, Open Label Clinical Study of CAR-T Cells Targeting GPRC5D in the Treatment of Relapsed / Refractory Multiple Myeloma (POLARIS)
First Posted: August 23, 2021
Click here to see details on ClinicalTrials.gov
GPRC5D CAR T-cells (OriCAR-017)
Meeting: 2022 ASCO Annual Meeting - Session Type: Oral Abstract Session - Session Title: Hematologic Malignancies—Plasma Cell Dyscrasia - Track: Hematologic Malignancies - Sub Track: Hematologic Malignancies - Clinical Trial Registration Number: NCT05016778
Abstract#: 8004 - Phase I open-label single arm study of GPRC5D CAR T-cells (OriCAR-017) in patients with relapsed/refractory multiple myeloma (POLARIS).
ABSTRACTS & PRESENTATIONS
2022 ASCO ANNUAL MEETING - June 3-7, 2022 - McCormick Place, Chicago, IL - Hybrid Meeting
2022 ASCO Annual Meeting - Oral Abstract Session
The clinical data summary of ori-CAR-017, the original CAR-T candidate product, was selected for the oral report of the 2022 ASCO Annual Meeting
2022-04-18: Yuan Qi Bio, a biopharmaceutical company committed to becoming the global creator of innovative drugs for tumor immunology, today officially announced that the latest clinical data of its independent innovation product, OriCAR-017 for the treatment of relapsed/refractory multiple myeloma (RRMM), was successfully selected for the oral presentation session of the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting, and the detailed data will be published in the form of oral reports.
EXPRESS: ONCE AGAIN ON THE WORLD STAGE, THE ORIGINAL CAR-T CLINICAL DATA WAS SELECTED FOR THE 2022 EHA ANNUAL MEETING
2022-05-06: Yuan Qi Bio, a biopharmaceutical company committed to becoming the creator of innovative drugs for tumor immunology in the world, today announced that the latest clinical data of its independent innovation product OriCAR-017 for the treatment of relapsed/refractory multiple myeloma (RRMM) appeared at the top international academic conference and was successfully selected for the 27th European Hematology Congress (27th EHA Congress) / Annual Conference in 2022, when detailed data will be released in the form of oral reports. OriCAR-017 is an innovative target CAR-T product developed by Hara Biotech based on its independent innovation oriAb and OriCAR technology platform.
RELATED GPRC5D POSTS
NCT04555551: Phase 1 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for Multiple Myeloma
NCT05431608: Phase 1: A Study of MCARH109 and MCARH125 in People With Multiple Myeloma
NCT05219721: Phase 1: A Study of CAR-GPRC5D in Patients With RRMM Myeloma or Plasma Cell Leukemia
NCT05509530: Phase 2: Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating RRMM
NCT04634552: Phase 2 - A Study of Talquetamab in Participants With Refractory Multiple Myeloma
NCT03399799: Phase 1 - Talquetamab, a Humanized GPRC5D x CD3 Bis Ab - Ref MM - MonumenTAL-1
NCT04773522: Phase 1 - JNJ-64407564 in Japanese Participants With Relapsed or Refractory Myeloma